Benzinga | Oct 7, 2021 08:10AM EDT

Editas Medicine To Present Preclinical Data On Novel Engineered iPSC Derived NK Cells For The Treatment Of Cancer At The Society For Immunotherapy Of Cancer 36Th Annual Meeting

Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that the Company will present preclinical data on its progress in the development of cell therapy medicines for the treatment of cancer at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting being held in Washington, D.C., and virtually, November 10-14, 2021.

The Company will present a poster on its new method to drive high-level constitutive CD16 expression on the surface of iPSC-derived natural killer (iNK) cells through transgene knock-in (KI) at the GAPDH locus using an Editas-engineered AsCas12a. New preclinical data demonstrated that CD16 KI confers significantly increased cytotoxic activity in iNK cells against tumor cells compared with wild type iNK cells.

Full details of the Editas Medicine presentation can be accessed on the SITC website at https://sitc.sitcancer.org/2021/abstracts/titles/.

Poster Presentation:

Title: GAPDH Knock-in of High Affinity CD16 in iPSC Derived NK Cells Drives High-level Expression and Increased Anti-tumor Function

Date and Time: Friday, November 12, 2021, 7:00 a.m. -- 8:30 p.m. ET

Abstract #: 191

Session Title: Cellular Therapies